Quantum Biopharma (QNTM) Cash & Equivalents (2018 - 2026)

Quantum Biopharma has disclosed Cash & Equivalents across 9 years of filings, most recently posting $1.9 million for Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $1.9 million, down 68.22% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.9 million (down 68.22% YoY), and the FY2025 annual result was $1.9 million, down 68.22% from the prior year.
• Cash & Equivalents came in at $1.9 million for Q1 2026 at Quantum Biopharma, roughly flat from $1.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $35.3 million in Q1 2022 to a low of $1.9 million in Q4 2025.
• The 5-year median for Cash & Equivalents is $6.0 million (2024), against an average of $11.7 million.
• Across the five-year window, Cash & Equivalents tumbled 83.76% in 2024 and soared 117.47% in 2025, its largest moves.
• Quantum Biopharma's Cash & Equivalents stood at $17.0 million in 2022, then changed by 0.0% to $17.0 million in 2023, then sank by 64.69% to $6.0 million in 2024, then slumped by 68.22% to $1.9 million in 2025, then changed by 0.0% to $1.9 million in 2026.
• The last three Cash & Equivalents figures came in at $1.9 million (Q1 2026), $1.9 million (Q4 2025), and $6.0 million (Q3 2025), per Business Quant data.